STOCKSCREENR

ESPR

NASDAQ

Esperion Therapeutics, Inc.

$2.71+0.02(+0.74%)Mkt Cap: $535.31M

Key Stats

Market Cap

$535.31M

P/E Ratio

-5.02

EPS

$-0.54

Dividend Yield

0.00%

52-Week Range

$0.69 — $4.18

Volume

4.09M

Avg Volume

5.02M

Beta

1.11

Valuation

P/E (TTM)

-5.02

Forward P/E

15.75

PEG Ratio

-0.38

P/S (TTM)

1.32

P/B (TTM)

-2.12

P/FCF

EV/EBITDA

EV/Sales

Financial Health

ROE (TTM)

0.06%

ROA (TTM)

-0.05%

ROIC

Gross Margin

0.30%

Operating Margin

0.15%

Net Margin

Debt/Equity

-0.50

Current Ratio

0.56

Growth

EPS Growth (YoY)

Revenue Growth (YoY)

EPS Growth (3Y)

+0.67%

EPS Growth (5Y)

+0.13%

Sales Growth (3Y)

+0.79%

Sales Growth (5Y)

+0.45%

EPS Est (This Year)

$0.17

EPS Est (Next Year)

$0.22

Dividends

Dividend Yield

Annual Dividend

Payout Ratio

Frequency

Ex-Dividend Date

Cash/Share

$0.71

Analyst Consensus

Ownership

Institutional %

Inst. Net Change

Insider Net Shares (90d)

Outstanding Shares

197.53M

Float

234.92M

Free Float %

118.93%

About

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

NASDAQ

IPO Date

2013-06-26

Employees

304

CEO

Sheldon L. Koenig

Index Membership

Website

https://www.esperion.com

Esperion Therapeutics, Inc. (ESPR) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $535.31M, a P/E ratio of -5.02, ESPR is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ESPR against other stocks using dozens of fundamental and technical filters.

Similar Stocks

Frequently Asked Questions

What is Esperion Therapeutics, Inc.'s P/E ratio?

Esperion Therapeutics, Inc. (ESPR) has a trailing twelve-month (TTM) P/E ratio of -5.02. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Esperion Therapeutics, Inc. pay a dividend?

No, Esperion Therapeutics, Inc. (ESPR) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Esperion Therapeutics, Inc.'s market cap?

Esperion Therapeutics, Inc. (ESPR) has a market capitalization of $535.31 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.